Published in Cancer Growth Metastasis on August 17, 2009
Molecular imaging with nucleic acid aptamers. Curr Med Chem (2011) 0.96
Molecular imaging of macrophage protease activity in cardiovascular inflammation in vivo. Thromb Haemost (2011) 0.95
In vivo magnetic resonance imaging of tumor protease activity. Sci Rep (2014) 0.83
Free-radical polymer science structural cancer model: a review. Scientifica (Cairo) (2013) 0.78
Characterization of the Tumor Microenvironment and Tumor-Stroma Interaction by Non-invasive Preclinical Imaging. Front Oncol (2017) 0.75
New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 24.71
Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer (2002) 17.49
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release (2000) 14.89
Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (2002) 12.29
Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev (2003) 11.29
Imaging in the era of molecular oncology. Nature (2008) 11.10
Tumor metastasis: mechanistic insights and clinical challenges. Nat Med (2006) 11.06
Looking and listening to light: the evolution of whole-body photonic imaging. Nat Biotechnol (2005) 9.57
In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol (1999) 8.46
Emerging roles of caspase-3 in apoptosis. Cell Death Differ (1999) 8.05
Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer (2002) 7.79
Molecular imaging. Radiology (2001) 5.67
Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer (2006) 5.58
Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer (2006) 5.06
Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol (2000) 4.98
Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci U S A (2004) 4.95
Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov (2006) 4.39
Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell (2004) 4.38
In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med (2001) 4.30
Multimodality molecular imaging of tumor angiogenesis. J Nucl Med (2008) 3.99
Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann Biomed Eng (2006) 3.67
Scaling down imaging: molecular mapping of cancer in mice. Nat Rev Cancer (2002) 3.04
Dynamic imaging of protease activity with fluorescently quenched activity-based probes. Nat Chem Biol (2005) 2.90
Optical imaging: current applications and future directions. J Nucl Med (2007) 2.84
Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. Nat Chem Biol (2007) 2.80
Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell (1998) 2.75
Nanoplatforms for targeted molecular imaging in living subjects. Small (2007) 2.69
Real-time catheter molecular sensing of inflammation in proteolytically active atherosclerosis. Circulation (2008) 2.52
Colonic adenocarcinomas: near-infrared microcatheter imaging of smart probes for early detection--study in mice. Radiology (2007) 2.29
Cathepsin D--many functions of one aspartic protease. Crit Rev Oncol Hematol (2008) 2.26
Optical imaging of matrix metalloproteinase-2 activity in tumors: feasibility study in a mouse model. Radiology (2001) 2.24
Optical visualization of cathepsin K activity in atherosclerosis with a novel, protease-activatable fluorescence sensor. Circulation (2007) 2.20
Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease. Circulation (2009) 2.07
Imaging of integrins as biomarkers for tumor angiogenesis. Curr Pharm Des (2008) 2.04
Near-infrared optical imaging of protease activity for tumor detection. Radiology (1999) 1.97
Cysteine cathepsins in human cancer. Biol Chem (2004) 1.91
Fabrication and characterization of a 0.5-mm lutetium oxyorthosilicate detector array for high-resolution PET applications. J Nucl Med (2007) 1.87
Spatial resolution and sensitivity of the Inveon small-animal PET scanner. J Nucl Med (2009) 1.80
Luciferin derivatives for enhanced in vitro and in vivo bioluminescence assays. Biochemistry (2006) 1.67
Development of a novel fluorogenic proteolytic beacon for in vivo detection and imaging of tumour-associated matrix metalloproteinase-7 activity. Biochem J (2004) 1.65
Building and breeding molecules to spy on cells and tumors. FEBS Lett (2005) 1.64
Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy. Lancet Oncol (2007) 1.61
Preparation of a cathepsin D sensitive near-infrared fluorescence probe for imaging. Bioconjug Chem (1999) 1.56
In vivo imaging of protease activity in arthritis: a novel approach for monitoring treatment response. Arthritis Rheum (2004) 1.55
Imaging matrix metalloproteinases in cancer. Cancer Metastasis Rev (2008) 1.54
Protease sensors for bioimaging. Anal Bioanal Chem (2003) 1.48
Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis. Drug Discov Today (2001) 1.46
A near-infrared-fluorescence-quenched gold-nanoparticle imaging probe for in vivo drug screening and protease activity determination. Angew Chem Int Ed Engl (2008) 1.43
Photodynamic molecular beacon as an activatable photosensitizer based on protease-controlled singlet oxygen quenching and activation. Proc Natl Acad Sci U S A (2007) 1.38
The matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) genes. Transcriptional and posttranscriptional regulation, signal transduction and cell-type-specific expression. Methods Mol Biol (2001) 1.38
Small-animal SPECT and SPECT/CT: important tools for preclinical investigation. J Nucl Med (2008) 1.35
Imaging of differential protease expression in breast cancers for detection of aggressive tumor phenotypes. Radiology (2002) 1.34
Cathepsin D: a cellular roadmap. Biochem Biophys Res Commun (2008) 1.33
Are quantum dots ready for in vivo imaging in human subjects? Nanoscale Res Lett (2007) 1.30
Optical imaging of matrix metalloproteinase-7 activity in vivo using a proteolytic nanobeacon. Mol Imaging (2009) 1.25
Optical imaging of spontaneous breast tumors using protease sensing 'smart' optical probes. Invest Radiol (2005) 1.22
Biomarkers of apoptosis: release of cytochrome c, activation of caspase-3, induction of 8-hydroxy-2'-deoxyguanosine, increased 3-nitrotyrosine, and alteration of p53 gene. J Toxicol Environ Health B Crit Rev (2001) 1.19
Protease-modulated cellular uptake of quantum dots. Nano Lett (2006) 1.19
Molecular imaging of proteolytic activity in cancer. J Cell Biochem (2003) 1.19
In vivo tomographic imaging of near-infrared fluorescent probes. Mol Imaging (2003) 1.19
Noninvasive detection of matrix metalloproteinase activity in vivo using a novel magnetic resonance imaging contrast agent with a solubility switch. Mol Imaging (2007) 1.18
Design, synthesis, and characterization of urokinase plasminogen-activator-sensitive near-infrared reporter. Chem Biol (2004) 1.15
Enzyme-targeted fluorescent imaging probes on a multiple antigenic peptide core. J Med Chem (2006) 1.13
In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis. Mol Ther (2005) 1.12
Novel solubility-switchable MRI agent allows the noninvasive detection of matrix metalloproteinase-2 activity in vivo in a mouse model. Magn Reson Med (2008) 1.07
Homogeneous, bioluminescent protease assays: caspase-3 as a model. J Biomol Screen (2005) 1.06
A functional proteomics screen of proteases in colorectal carcinoma. Mol Med (2000) 1.06
Enzyme activity--it's all about image. Trends Cell Biol (2004) 1.05
Bioluminescent imaging of TRAIL-induced apoptosis through detection of caspase activation following cleavage of DEVD-aminoluciferin. Cancer Biol Ther (2005) 1.04
Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). Int J Pharm (2004) 1.02
Improving the evaluation of new cancer treatments: challenges and opportunities. Nat Rev Cancer (2003) 1.01
Molecular and functional imaging of cancer: advances in MRI and MRS. Methods Enzymol (2004) 1.00
Molecular imaging of myocardial infarction. J Mol Cell Cardiol (2006) 0.99
Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies. Int J Oncol (1998) 0.98
The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer. Anticancer Drugs (2001) 0.98
The year(s) of the contrast agent - micro-MRI in the new millennium. Curr Opin Immunol (2003) 0.96
Protease-specific nanosensors for magnetic resonance imaging. Bioconjug Chem (2008) 0.95
Molecular Imaging with Single-Walled Carbon Nanotubes. Nano Today (2009) 0.95
Radionuclide imaging of tumor xenografts in mice using a gelatinase-targeting peptide. Anticancer Res (2005) 0.94
In vitro and in vivo investigation of matrix metalloproteinase expression in metastatic tumor models. Nucl Med Biol (2006) 0.94
Cathepsin S in tumours, regional lymph nodes and sera of patients with lung cancer: relation to prognosis. Br J Cancer (2001) 0.93
Cathepsin K in melanoma invasion. J Invest Dermatol (2008) 0.93
New enzyme-activated solubility-switchable contrast agent for magnetic resonance imaging: from synthesis to in vivo imaging. J Med Chem (2009) 0.91
Use of fluorescent imaging to investigate pathological protease activity. Curr Opin Drug Discov Devel (2008) 0.91
Targeting of gelatinase activity with a radiolabeled cyclic HWGF peptide. Nucl Med Biol (2004) 0.91
Tumor detection using 18F-labeled matrix metalloproteinase-2 inhibitor. Nucl Med Biol (2003) 0.90
Cathepsin B: multiple enzyme forms from a single gene and their relation to cancer. Enzyme Protein (1996) 0.89
Imaging cathepsin B up-regulation in HT-1080 tumor models using fluorescence-mediated molecular tomography (FMT). Acad Radiol (2002) 0.88
In vivo imaging of HIV protease activity in amplicon vector-transduced gliomas. Cancer Res (2004) 0.88
Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT): Clinical Applications. J Neuroophthalmol (2003) 0.87
Development of an optimized activatable MMP-14 targeted SPECT imaging probe. Bioorg Med Chem (2008) 0.86
C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging. J Med Chem (2005) 0.86
Imaging probes targeting matrix metalloproteinases. Cancer Biother Radiopharm (2006) 0.85
New radioiodinated carboxylic and hydroxamic matrix metalloproteinase inhibitor tracers as potential tumor imaging agents. Nucl Med Biol (2004) 0.85
Synthesis and preliminary biological evaluation of new radioiodinated MMP inhibitors for imaging MMP activity in vivo. Nucl Med Biol (2004) 0.84
In-vivo imaging of tumor associated urokinase-type plasminogen activator activity. J Biomed Opt (2006) 0.84
A new 18F-labelled derivative of the MMP inhibitor CGS 27023A for PET: radiosynthesis and initial small-animal PET studies. Appl Radiat Isot (2008) 0.83
Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers [11C]methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents. Nucl Med Biol (2002) 0.83
Gadolinium meets medicinal chemistry: MRI contrast agent development. Curr Med Chem (2005) 0.82
In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol (2006) 6.93
Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy. Proc Natl Acad Sci U S A (2008) 4.89
Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. J Nucl Med (2006) 2.65
Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med (2011) 2.51
(64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J Nucl Med (2007) 2.50
Prevalence of unruptured cerebral aneurysms in Chinese adults aged 35 to 75 years: a cross-sectional study. Ann Intern Med (2013) 2.23
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res (2008) 2.13
Dynamic ventilation imaging from four-dimensional computed tomography. Phys Med Biol (2006) 1.80
Applications of gold nanoparticles in cancer nanotechnology. Nanotechnol Sci Appl (2008) 1.71
Positron emission tomography imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging (2011) 1.70
Structural basis of EZH2 recognition by EED. Structure (2007) 1.58
cRGD-functionalized, DOX-conjugated, and ⁶⁴Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Biomaterials (2011) 1.56
Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots. Eur J Nucl Med Mol Imaging (2008) 1.55
In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene. ACS Nano (2012) 1.53
Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105. Eur J Nucl Med Mol Imaging (2011) 1.50
PET tracers based on Zirconium-89. Curr Radiopharm (2011) 1.48
Molecular imaging and therapy of cancer with radiolabeled nanoparticles. Nano Today (2009) 1.47
microPET of tumor integrin alphavbeta3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4). J Nucl Med (2007) 1.46
Near-infrared fluorescence imaging of tumor integrin alpha v beta 3 expression with Cy7-labeled RGD multimers. Mol Imaging Biol (2006) 1.46
A new PET tracer specific for vascular endothelial growth factor receptor 2. Eur J Nucl Med Mol Imaging (2007) 1.43
Positron Emission Tomography and Near-Infrared Fluorescence Imaging of Vascular Endothelial Growth Factor with Dual-Labeled Bevacizumab. Am J Nucl Med Mol Imaging (2012) 1.41
18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med (2006) 1.37
Positron emission tomography imaging of CD105 expression with a 64Cu-labeled monoclonal antibody: NOTA is superior to DOTA. PLoS One (2011) 1.36
Quantification of regional ventilation from treatment planning CT. Int J Radiat Oncol Biol Phys (2005) 1.36
In vivo tumor targeting and image-guided drug delivery with antibody-conjugated, radiolabeled mesoporous silica nanoparticles. ACS Nano (2013) 1.34
Graphene: a versatile nanoplatform for biomedical applications. Nanoscale (2012) 1.32
Noninvasive de novo imaging of human embryonic stem cell-derived teratoma formation. Cancer Res (2009) 1.28
Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging. Biomaterials (2012) 1.27
Mouse corneal lymphangiogenesis model. Nat Protoc (2011) 1.27
Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel. J Nucl Med (2007) 1.26
Tumor vasculature targeting and imaging in living mice with reduced graphene oxide. Biomaterials (2013) 1.26
Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis. Proc Natl Acad Sci U S A (2012) 1.23
Copper-catalyzed synthesis of N-fused heterocycles through regioselective 1,2-aminothiolation of 1,1-dibromoalkenes. Org Lett (2010) 1.20
Multimodality molecular imaging of CD105 (Endoglin) expression. Int J Clin Exp Med (2010) 1.16
Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiforme. Clin Cancer Res (2008) 1.14
Multimodality imaging of breast cancer experimental lung metastasis with bioluminescence and a monoclonal antibody dual-labeled with 89Zr and IRDye 800CW. Mol Pharm (2012) 1.14
ImmunoPET and near-infrared fluorescence imaging of CD105 expression using a monoclonal antibody dual-labeled with (89)Zr and IRDye 800CW. Am J Transl Res (2012) 1.14
Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional Brca1 in ovarian granulosa cells. Curr Biol (2005) 1.14
Graphene based tunable metamaterial absorber and polarization modulation in terahertz frequency. Opt Express (2014) 1.12
Hexamodal imaging with porphyrin-phospholipid-coated upconversion nanoparticles. Adv Mater (2015) 1.11
Positron emission tomography imaging of prostate cancer. Amino Acids (2009) 1.11
Gold Nanorods Conjugated with Doxorubicin and cRGD for Combined Anticancer Drug Delivery and PET Imaging. Theranostics (2012) 1.11
Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer. Med Oncol (2012) 1.10
Multimodality Imaging of Integrin α(v)β(3) Expression. Theranostics (2011) 1.10
Preparation and functionalization of graphene nanocomposites for biomedical applications. Nat Protoc (2013) 1.10
Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues. Proc Natl Acad Sci U S A (2013) 1.09
Imaging of VEGF receptor in a rat myocardial infarction model using PET. J Nucl Med (2008) 1.09
In vivo targeting and positron emission tomography imaging of tumor vasculature with (66)Ga-labeled nano-graphene. Biomaterials (2012) 1.07
Semiconductor quantum dots for in vivo imaging. J Nanosci Nanotechnol (2007) 1.07
Monitoring of the biological response to murine hindlimb ischemia with 64Cu-labeled vascular endothelial growth factor-121 positron emission tomography. Circulation (2008) 1.07
Non-invasive cell tracking in cancer and cancer therapy. Curr Top Med Chem (2010) 1.07
Chelator-free synthesis of a dual-modality PET/MRI agent. Angew Chem Int Ed Engl (2013) 1.05
ERCP after bypass surgery. Which option would patients prefer? Endoscopy (2014) 1.05
HaloTag: a novel reporter gene for positron emission tomography. Am J Transl Res (2011) 1.04
PET imaging of CD105/endoglin expression with a ⁶¹/⁶⁴Cu-labeled Fab antibody fragment. Eur J Nucl Med Mol Imaging (2013) 1.03